TrialJNCI cancer spectrum2024
A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer.
Patrick M Boland et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it